

This listing of claims will replace all prior versions, and listings, of claims in the application:

1 - 16 (Canceled).

~~17~~¹ (Currently amended) A method of treating ~~a condition resulting in~~ bone loss, which comprises administering an IL-1 inhibitor, a TNF- α inhibitor, and an OPG protein, wherein "OPG protein" refers to ~~an antibody to OPG ligand or~~ a polypeptide comprising conserved residues from residues 22 to 185 of SEQ ID NOS: 121, 123, and 125.

~~18~~² (Original). The method of Claim ~~17~~¹, wherein the TNF- α inhibitor comprises sTNFR-I, sTNFR-II, sTNFR fragments, or sTNFR-Fc, wherein "sTNFR" refers to sTNFR-I or sTNFR-II.

~~19~~ (Currently amended) ~~The method of Claim 17, wherein the TNF- α [[\square]] inhibitor comprises sTNFR-I, sTNFR-II, sTNFR fragments, or sTNFR-Fc, wherein "sTNFR" refers to sTNFR-I or sTNFR-II.~~

~~20~~⁵ (Currently amended). The method of claim ~~17~~¹, wherein the TNF- α [[TNF α]] inhibitor comprises 30 kD PEG-sTNFR-I.

~~21~~³ (Previously presented). The method of claim ~~18~~², wherein the sTNFR fragment is a 2.6 kD sTNFR-I fragment.

~~22~~⁴ (Previously presented). The method of claim ~~21~~³, wherein the sTNFR-I fragment comprises 30 kD PEG.

~~23~~⁶ (Original). The method of claim ~~17~~¹, wherein the TNF α inhibitor comprises sTNFR-II linked to an Fc region.

7 ~~24~~. (Currently amended). The method of claim 1¹~~7~~, wherein the TNF- α [[TNF α]] inhibitor is etanercept.

8 ~~25~~. (Original). The method of Claim 1¹~~7~~, wherein the OPG protein is OPG-Fc.

Claim 26-38 (Canceled).

9 ~~39~~. (Currently amended) The method of any of claims 1¹~~7~~ to 8⁸~~25~~, wherein the bone loss results from condition treated is rheumatoid arthritis.

10 ~~40~~. (Currently amended) The method of any of claims 1¹~~7~~ to 8⁸~~25~~, wherein the bone loss results from condition treated is multiple sclerosis.

11 ~~41~~. (Currently amended) The method of any of claims 1¹~~7~~ to 8⁸~~25~~, wherein the bone loss results from condition treated is osteoporosis.

12 ~~42~~. (Currently amended) The method of any of claims 1¹~~7~~ to 8⁸~~25~~, wherein the bone loss results from condition treated is osteomyelitis.

Claim 43 - 61 (Canceled).

13 ~~62~~. (Previously presented) The method of Claim 1¹~~7~~, wherein the OPG protein comprises a sequence comprising the conserved residues from residues 22 to 185 of SEQ ID NOS: 171, 172, and 173.

14 ~~63~~. (Previously presented) The method of Claim 1¹~~7~~, wherein the OPG protein comprises residues 22 to 185 of SEQ ID NO: 123.

15 ~~64~~. (Previously presented) The method of Claim 1¹~~7~~, wherein the OPG protein comprises residues 22 to 185 of SEQ ID NO: 125.